Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma |
| |
| Affiliation: | 1. University of Nebraska Medical Center, Omaha, Nebraska;2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota;3. Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University, Durham, North Carolina;4. The Ohio State University Comprehensive Cancer Center, Columbus, Ohio;5. UNC Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina;6. University of California at San Francisco, San Francisco, California;7. University of Iowa, Iowa City, Iowa;8. Mount Sinai School of Medicine, New York, New York;9. Washington University School of Medicine, St. Louis, Missouri;10. MedStar Georgetown University Hospital, Washington, DC;11. Dana-Farber/Partners CancerCare, Boston, Massachusetts;12. Roswell Park Comprehensive Cancer Center, Buffalo, New York |
| |
| Abstract: | CALGB (Alliance) 100001 was a phase II study evaluating autologous stem cell transplant (ASCT) followed by nonmyeloablative allogeneic stem cell transplant (alloSCT) in patients with multiple myeloma who had received no more than 18 months of prior therapy and had experienced no more than 1 prior progression event. Conditioning for ASCT was with high-dose melphalan (200 mg/m2). The alloSCT reduced-intensity conditioning (RIC) regimen consisted of fludarabine (30 mg/m2/d i.v. on days -7 through -3) and cyclophosphamide (1 g/m2/d i.v. on days -4 through -3). The primary objective was to determine the 6-month post-alloSCT treatment-related mortality (TRM) rate. Additional objectives included determining the proportion of patients who could complete this tandem ASCT-alloSCT approach in a cooperative group setting, overall response rates, rates of donor chimerism, rates of graft-versus-host disease (GVHD), disease-free survival, and overall survival (OS). Sixty patients were enrolled, of whom 57 (95%) completed ASCT and 49 (82%) completed tandem ASCT-alloSCT. The TRM rate was 2% (1/49; 90% confidence interval, 0.10% to 9.3%). Moderate to severe (grades 2 to 3) acute GVHD was observed in 13 of 49 alloSCT patients (27%). One patient died due to GVHD within 9 months of alloSCT. Twenty-seven of the 49 patients (55%) who underwent alloSCT reported chronic GVHD as either limited (15/49; 31%) or extensive (12/49; 24%) in the first year post-alloSCT and prior to the start of nonprotocol therapy for progressive disease. With a median follow-up for survival of 11 years, the median OS time is 6.6 years and the median time to disease progression is 3.6 years. Similar to other studies, this study confirmed that tandem ASCT/alloSCT is associated with durable disease control in a subset of patients. This study demonstrated the feasibility of performing tandem ASCT/alloSCT in a cooperative group setting and determined that a fludarabine/cyclophosphamide RIC regimen is associated with a very low TRM rate. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
